New hope for men with prostate cancer
Listen to a Urology Care Podcast, “What to Know About Penile Implants” with Dr. Melissa Mendez
The FDA has approved a 6-month subcutaneous depot formulation of leuprolide mesylate as a ready-to-use treatment for patients with advanced prostate cancer.
Patients with oligometastatic disease have a more favorable prognosis than those with widespread metastatic disease.
Younger Black men have a significantly higher risk for prostate cancer and a higher risk of dying from prostate cancer compared with white men.
Steven N. Gange, MD, FACS, presented “Focal Therapy Compared to Radical Prostatectomy” for the Grand Rounds in Urology audience in May 2021.